pT1a-b 期淋巴结阴性乳腺癌的特征及临床结局

Characteristics and clinical outcome of pT1a-b node-negative breast cancer.

作者信息

Oyman Abdilkerim, Basak Mustafa, Odabas Hatice, Ozcelik Melike

机构信息

Department of Medical Oncology, University of Health Sciences Umraniye Training and Research Hospital, Istanbul, Turkey.

Department of Medical Oncology, Dr. Lutfi Kirdar Kartal Training and Research Hospital, Istanbul, Turkey.

出版信息

North Clin Istanb. 2021 Mar 24;8(2):124-129. doi: 10.14744/nci.2020.06332. eCollection 2021.

DOI:10.14744/nci.2020.06332

PMID:33851075

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8039097/

Abstract

OBJECTIVE

Tumor size, along with other clinicopathological characteristics, has a prognostic role in breast cancer. Recurrence risk tends to rise as tumor size increases. Early T-stage portends a good prognosis. We aimed to investigate the recurrence-free interval rates of T1abN0 group of early breast cancer.

METHODS

Patients diagnosed with pT1a and T1b, lymph node metastasis-negative breast cancer were included in the study. Clinicopathologic characteristics including recurrence, distant metastasis, and final status of the patients were obtained retrospectively from the patient files.

RESULTS

A total of 84 patients included. Twenty-six patients (31%) had T1a and 58 patients (69%) had T1b tumors. The 5-year distant relapse-free survival (DRFS) rate of T1ab tumors was 95.2%. The DRFS rate of T1a tumors was 96.2%, while the rate of T1b tumors was 94.8% (p=0.555). The 5-year RFS rate of T1ab tumors was 90.5%. The RFS rate of T1a tumors was 84.6%, whereas the rate of T1b tumors was 93.1% (p=0.359). The 5-year DRFS rate of hormone receptor positive group was 97%, Her-2 positive group was 81.8%, and triple negative group was 100% (p=0.041). The 5-year RFS rate of the hormone receptor positive group was 97%, Her-2 positive group was 72.7%, and triple negative group was 57.1% (p=0.001).

CONCLUSION

The results of the study provided that both T1a and T1b tumors have a good and similar prognosis.

摘要

目的

肿瘤大小与其他临床病理特征一样，在乳腺癌中具有预后作用。复发风险往往随着肿瘤大小的增加而上升。早期T分期预示着良好的预后。我们旨在研究早期乳腺癌T1abN0组的无复发生存率。

方法

本研究纳入诊断为pT1a和T1b、无淋巴结转移的乳腺癌患者。回顾性地从患者病历中获取包括复发、远处转移和患者最终状态在内的临床病理特征。

结果

共纳入84例患者。26例（31%）为T1a肿瘤，58例（69%）为T1b肿瘤。T1ab肿瘤的5年远处无复发生存率（DRFS）为95.2%。T1a肿瘤的DRFS率为96.2%，而T1b肿瘤的DRFS率为94.8%（p = 0.555）。T1ab肿瘤的5年无复发生存率（RFS）为90.5%。T1a肿瘤的RFS率为84.6%，而T1b肿瘤的RFS率为93.1%（p = 0.359）。激素受体阳性组的5年DRFS率为97%，Her-2阳性组为81.8%，三阴性组为100%（p = 0.041）。激素受体阳性组的5年RFS率为97%，Her-2阳性组为72.7%，三阴性组为57.1%（p = 0.001）。